1. Home
  2. SWBI vs PRTA Comparison

SWBI vs PRTA Comparison

Compare SWBI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith & Wesson Brands Inc.

SWBI

Smith & Wesson Brands Inc.

HOLD

Current Price

$14.86

Market Cap

491.2M

Sector

Industrials

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.81

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWBI
PRTA
Founded
1852
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
491.2M
539.9M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
SWBI
PRTA
Price
$14.86
$10.81
Analyst Decision
Strong Buy
Buy
Analyst Count
1
9
Target Price
$14.00
$19.00
AVG Volume (30 Days)
625.0K
453.1K
Earning Date
03-05-2026
05-07-2026
Dividend Yield
3.50%
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$474,661,000.00
$814,000.00
Revenue This Year
$7.61
$1,111.38
Revenue Next Year
$3.72
N/A
P/E Ratio
$296.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.73
$4.32
52 Week High
$15.40
$11.69

Technical Indicators

Market Signals
Indicator
SWBI
PRTA
Relative Strength Index (RSI) 62.55 67.15
Support Level $13.65 $9.69
Resistance Level $15.24 $10.90
Average True Range (ATR) 0.45 0.40
MACD -0.09 0.10
Stochastic Oscillator 74.90 96.87

Price Performance

Historical Comparison
SWBI
PRTA

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: